Because Bcr–Abl is destabilized and degraded upon Hsp90 inhibition, it may represent a new opportunity for blocking CML progression in Bcr–Abl mutations associated with a drug-resistant phenotype (73). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.